North Dakota 2025-2026 Regular Session

North Dakota Senate Bill SB2064

Introduced
1/7/25  
Refer
1/7/25  
Report Pass
1/10/25  
Engrossed
1/14/25  
Refer
2/13/25  
Report Pass
3/11/25  
Enrolled
3/24/25  

Caption

The scheduling of controlled substances; and to declare an emergency.

Companion Bills

No companion bills found.

Previously Filed As

ND SB2093

The scheduling of controlled substances; and to declare an emergency.

ND HB1459

Increased penalties for drug offenses within three hundred feet of a public park; and to provide a penalty.

ND SB2096

Definitions, prohibited acts by licensees, schedule I controlled substances tetrahydrocannabinols, and bonding requirements for grain buyers; and to provide a penalty.

ND SB2103

Child abuse and neglect, the child abuse information index, disclosure of records for child protection purposes, prenatal exposure to controlled substances and alcohol, and alternative response assessments.

ND HB1321

Retirement board membership; to provide an effective date; and to declare an emergency.

ND SB2164

Retirement board membership; to provide an effective date; and to declare an emergency.

ND SB2317

Amalgamating property interests; and to declare an emergency.

ND SB2150

Abortions, sex-selective abortions, genetic abnormality abortions, human dismemberment abortions, and abortions after a detectable heartbeat; to provide a penalty; and to declare an emergency.

ND HB1254

The prohibition of certain practices against a minor; to provide a penalty; and to declare an emergency.

ND SB2118

Abandoned motor vehicles; and to declare an emergency.

Similar Bills

ND SB2093

The scheduling of controlled substances; and to declare an emergency.

SD SB35

Modify substances listed on the controlled substances schedule and to declare an emergency.

IN SB0209

Drug schedules.

IN SB0379

Drug schedules.

VA SB932

Virginia Psilocybin Advisory Board; established, report.

WV HB2854

Removing certain drugs from schedule one

WV HB3343

Relating to drugs and adding a provision relating to the scheduling of crystalline polymorph psilocybin approved by the Food and Drug Administration